11/11/2009

Sanofi-Aventis will extend a drug-development agreement with Regeneron Pharmaceuticals and invest an additional $1 billion in the biotech firm over eight years. Regeneron has four monoclonal antibodies in clinical studies and plans to put four or five candidates in human trials annually under the deal.

Related Summaries